icon

Shares of Advanced Cell Technology (ACTC) have remained relatively stable while trading for - or just below - twenty cents since rising from below a dime on news that the FDA had given an historical greent light to initiate clinical trials utilizing utilizing ACT's stem cell technology to treat severe vision loss.

Until that point, only GERN - for the treatment of spinal cord injuries - had been authorized to conduct such a stem-cell based trial.

ACT announced on Monday morning that the "Casey Eye Institute (CEI) at Oregon Health & Science University (OHSU) in Portland, Ore., has received institutional review board (IRB) approval to be a site for its Phase 1/2 human clinical trial for Stargardt's Macular Dystrophy (SMD)," according to a press release issued by the company.

The Jules Stein Institute at the University of California has also previously received IRB approval.

Having already put itself on the embryonic stem cell map, ACT is cementing itself as a legitimate player in the sector.  While GERN receives all the attention, don't forget about ACTC.

In addition to preparing for trials in the United States, where ACT has already received an orphan drug status from the FDA for the SMD indication, the company is also bringing its technology across the pond.

The share price remained flat on this news, and it's my opinion that the current market cap for ACTC is justified, based on the current stage of the pipeline.  That said, the stem-cell sector is a new one, and can heat up on a moment's notice, as previous price runs with GERN have demonstrated.

I've long felt that GERN was overvalued - based on the stages of its pipeline - although it's alot more attractive a pick while trading in the fours than it was for seven-plus.

Keep an eye on ACTC.  There is some potential for a dip, in my opinion (where I'll look to re-enter), back into the mid teens, but over the long run, this could be a game changer.

Disclosure:  No position.

Add a Comment